Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study

BMC Pulmonary Medicine

Volumn 14, Issue 1, 2014, Pages

  Watz, Henrik ^a   Krippner, Felix ^b   Kirsten, Anne ^a   Magnussen, Helgo ^a   Vogelmeier, Claus ^c  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Bronchodilator treatment; Chronic obstructive pulmonary disease; Lung hyperinflation; Physical activity

Indexed keywords

INDACATEROL; PLACEBO; SALBUTAMOL; THEOPHYLLINE; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

ABNORMAL LABORATORY RESULT; ADULT; AIRWAY RESISTANCE; ARTICLE; BACKACHE; BODY PLETHYSMOGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; INSPIRATORY RESERVE VOLUME; LUNG FUNCTION; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RESPIROMETRY; RHINITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TOTAL LUNG CAPACITY; TREATMENT DURATION; ACTIMETRY; AGED; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; IMPEDANCE PLETHYSMOGRAPHY; MIDDLE AGED; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

ACTIGRAPHY; AGED; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; INSPIRATORY CAPACITY; MALE; MIDDLE AGED; MOTOR ACTIVITY; PLETHYSMOGRAPHY, IMPEDANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SCOPOLAMINE DERIVATIVES; SPIROMETRY;

EID: 84908066729     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-14-158     Document Type: Article

References (35)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365. 10.1164/rccm.201204-0596PP, 22878278.
2. Ferguson GT. Why does the lung hyperinflate?. Proc Am Thorac Soc 2006, 3:176-179. 10.1513/pats.200508-094DO, 16565428.
3. O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007, 4:225-236. 10.1080/15412550701480455, 17729066.
4. Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, Lopez-Collazo E, Alvarez-Sala R. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009, 180:506-512. 10.1164/rccm.200812-1873OC, 19542481.
5. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J 2009, 33:262-272.
6. Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, Benzo R, Andre D, Weisman I, Decramer M. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med 2010, 104:1005-1011. 10.1016/j.rmed.2010.01.012, 3471783, 20167463.
7. Garcia-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM, Anto JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 2003, 58:100-105. 10.1136/thorax.58.2.100, 1746561, 12554887.
8. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006, 61:772-778. 10.1136/thx.2006.060145, 2117100, 16738033.
9. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest 2006, 129:536-544. 10.1378/chest.129.3.536, 16537849.
10. Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, Smith C, Man WD, Tal-Singer R, Edwards LD, Calverley PM, Magnussen H, Polkey MI, Wouters EF. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012, 106:522-530. 10.1016/j.rmed.2011.10.022, 22118987.
11. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh SL, Bloch SA, Sidhu PS, Hart N, Kemp PR, Moxham J, Polkey MI, Hopkinson NS. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012, 40:1115-1122. 10.1183/09031936.00170111, 22362854.
12. Waschki B, Kirsten A, Holz O, Muller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 2011, 140:331-342. 10.1378/chest.10-2521, 21273294.
13. Garcia-Rio F, Rojo B, Casitas R, Lores V, Madero R, Romero D, Galera R, Villasante C. Prognostic value of the objective measurement of daily physical activity in patients with COPD. Chest 2012, 142:338-346. 10.1378/chest.1388806, 22281798.
14. Beier J, Beeh KM. Long-acting beta-adrenoceptor agonists in the management of COPD: focus on indacaterol. Int J Chron Obstruct Pulmon Dis 2011, 6:237-243. 3144843, 21814459.
15. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med 2013, 13:26. 10.1186/1471-2466-13-26, 3651265, 23617268.
16. Beeh KM, Wagner F, Khindri S, Drollmann AF. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011, 8:340-345. 10.3109/15412555.2011.594464, 21793716.
17. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011, 105:1030-1036. 10.1016/j.rmed.2011.03.014, 21498063.
18. Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med 2012, 106:84-90. 10.1016/j.rmed.2011.09.006, 22035851.
19. Hataji O, Naito M, Ito K, Watanabe F, Gabazza EC, Taguchi O. Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2013, 8:1-5. 3534442, 23293514.
20. Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Effects if indacaterol on lung volumes and physical activity in moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:A2257.
21. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, Van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G. Standardisation of the measurement of lung volumes. Eur Respir J 2005, 26:511-522. 10.1183/09031936.05.00035005, 16135736.
22. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, Macintyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J 2005, 26:319-338. 10.1183/09031936.05.00034805, 16055882.
23. Criee CP, Sorichter S, Smith HJ, Kardos P, Merget R, Heise D, Berdel D, Kohler D, Magnussen H, Marek W, Mitfessel H, Rasche K, Rolke M, Worth H, Jorres RA. Body plethysmography-its principles and clinical use. Respir Med 2011, 105:959-971. 10.1016/j.rmed.2011.02.006, 21356587.
24. Hill K, Dolmage TE, Woon L, Goldstein R, Brooks D. Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease. Thorax 2010, 65:486-491. 10.1136/thx.2009.128702, 20522844.
25. Van Remoortel H, Raste Y, Louvaris Z, Giavedoni S, Burtin C, Langer D, Wilson F, Rabinovich R, Vogiatzis I, Hopkinson NS, Troosters T. Validity of six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect calorimetry. PLoS One 2012, 7:e39198. 10.1371/journal.pone.0039198, 3380044, 22745715.
26. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:180-184. 10.1513/pats.200508-093DO, 16565429.
27. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005, 2:111-124. 10.1081/COPD-200053377, 17136971.
28. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840. 10.1183/09031936.04.00116004, 15218994.
29. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003, 124:1743-1748. 10.1378/chest.124.5.1743, 14605043.
30. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 1985, 100:126-131. 1424733, 3920711.
31. Hartman JE, Boezen HM, De Greef MH, Bossenbroek L, Ten Hacken NH. Consequences of physical inactivity in chronic obstructive pulmonary disease. Expert Rev Respir Med 2010, 4:735-745. 10.1586/ers.10.76, 21128749.
32. Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, Chan HT, Tsao CK, Tsai SP, Wu X. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 2011, 378:1244-1253. 10.1016/S0140-6736(11)60749-6, 21846575.
33. Troosters T, Van der Molen T, Polkey M, Rabinovich RA, Vogiatzis I, Weisman I, Kulich K. Improving physical activity in COPD: towards a new paradigm. Respir Res 2013, 14:115. 10.1186/1465-9921-14-115, 4176094, 24229341.
34. Beeh KM, Beier J, Donohue JF. Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res 2012, 13:52. 10.1186/1465-9921-13-52, 3462669, 22726538.
35. Troosters T, Weisman I, Dobbels F, Giardino N, Valluri SR. Assessing the impact of tiotropium on lung function and physical activity in GOLD stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. Open Respir Med J 2011, 5:1-9. 10.2174/1874306401105010001, 3078679, 21503263.